18F-Florbetapir and 18F-FDG PET studies in the diagnostic evaluation of Alzheimer's disease

Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: The incremental diagnostic value of amyloid PET with [18F]-florbetapir (INDIA-FBP) study

Boccardi M.
Altomare D.
Ferrari C.
Festari C.
Guerra U. P.
Paghera B.
Pizzocaro C.
Lussignoli G.
Geroldi C.
Zanetti O.
Cotelli M. S.
Turla M.
Borroni B.
Rozzini L.
Mirabile D.
Defanti C.
Gennuso M.
Prelle A.
Gentile S.
Morandi A.
Vollaro S.
Volta G. D.
Bianchetti A.
Conti M. Z.
Cappuccio M.
Carbone P.
Bellandi D.
Abruzzi L.
Bettoni L.
Villani D.
Raimondi M. C.
Lanari A.
Ciccone A.
Facchi E.
Di Fazio I.
Rozzini R.
Boffelli S.
Manzoni L.
Salvi G. P.
Cavaliere S.
Belotti G.
Avanzi S.
Pasqualetti P.
Muscio C.
Padovani A.
Frisoni G. B.
Antelmi L.
Galluzzi S.
Pievani M.
Redolfi A.
Tarallo A.
Arora A.
Bertocchi M.
Chito E.
Moretti D. V.
Giubbini R.
Rodella C.
Camoni L.
Massetti V.
Andreoli M.
Bellelli G.
Fascendini S.
Mattioli F.
Turco R.
Vezzadini G.
Raimondi V.
Mondini S.
Zanacchi E. C.
Grigolo M.
Pezzini A.
Bilotti G.
Bigni B.
Zavarise P.
Ngonga G.
Anzola G. P.
Turrone R.
Guizzetti G.
Zanetti M.

January 2016

IMPORTANCE Cerebral amyloidosis is a key abnormality in Alzheimer disease (AD) and can be detected i...

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Camus, Vincent
Payoux, Pierre
Barré, Louisa
Desgranges, Béatrice
Voisin, Thierry
Tauber, Clovis
La Joie, Renaud
Tafani, Mathieu
Hommet, Caroline
Chételat, Gaël
Mondon, Karl
de La Sayette, Vincent
Cottier, Jean-Philippe
Beaufils, Emilie
Ribeiro, Maria-Joao
Gissot, Valérie
Vierron, Emilie
Vercouillie, Johnny
Skovronsky, D.
Vellas, Bruno
Eustache, Francis
Guilloteau, Denis

April 2012

International audiencePURPOSE: Positron emission tomography (PET) imaging of brain amyloid load has ...

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Camus, Vincent
Payoux, Pierre
Barré, Louisa
Desgranges, Béatrice
Voisin, Thierry
Tauber, Clovis
La Joie, Renaud
Tafani, Mathieu
Hommet, Caroline
Chételat, Gaël
Mondon, Karl
de La Sayette, Vincent
Cottier, Jean-Philippe
Beaufils, Emilie
Ribeiro, Maria-Joao
Gissot, Valérie
Vierron, Emilie
Vercouillie, Johnny
Skovronsky, D.
Vellas, Bruno
Eustache, Francis
Guilloteau, Denis

April 2012

International audiencePURPOSE: Positron emission tomography (PET) imaging of brain amyloid load has ...

18F-Florbetaben PET/CT to Assess Alzheimer's Disease: A new Analysis Method for Regional Amyloid Quantification

Alongi, Pierpaolo
Sardina, Davide Stefano
Coppola, Rosalia
Scalisi, Salvatore
Puglisi, Valentina
Arnone, Annachiara
Raimondo, Giorgio Di
Munerati, Elisabetta
Alaimo, Valerio
Midiri, Federico
Russo, Giorgio
Stefano, Alessandro
Giugno, Rosalba
Piccoli, Tommaso
Midiri, Massimo
Grimaldi, Luigi M E

January 2019

While AD can be definitively confirmed by postmortem histopathologic examination, in vivo imaging ma...

Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study

Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP)Working Group

January 2016

Cerebral amyloidosis is a key abnormality in Alzheimer disease (AD) and can be detected in vivo with...

The use of amyloid imaging in clinical praxis: a critical review

Nordberg, Agneta

February 2015

Recent development in molecular imaging enables measurement of fibrillar amyloid plaque in Alzheimer...

Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain

Richards, Danielle
Sabbagh, Marwan N.

December 2014

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting the elderly. Current ...

18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease

Filippi, Luca
Chiaravalloti, Agostino
Bagni, Oreste
Schillaci, Orazio

August 2018

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with tremendous impact...

18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease

Filippi, Luca
Chiaravalloti, Agostino
Bagni, Oreste
Schillaci, Orazio

August 2018

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with tremendous impact...

18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease

Filippi, Luca
Chiaravalloti, Agostino
Bagni, Oreste
Schillaci, Orazio

August 2018

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with tremendous impact...

18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease

Filippi, Luca
Chiaravalloti, Agostino
Bagni, Oreste
Schillaci, Orazio

August 2018

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with tremendous impact...

18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease

Filippi, L
Chiaravalloti, A
Bagni, O
Schillaci, O

August 2018

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with tremendous impact...

A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis

Perani Daniela
Schillaci Orazio
Padovani Alessandro
Nobili Flavio Mariano
Iaccarino Leonardo
Della Rosa Pasquale Anthony
Frisoni Giovanni
Caltagirone Carlo

January 2014

PET based tools can improve the early diagnosis of Alzheimer’s disease (AD) and differential diagnos...

Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia

Degenhardt, Elisabeth K.
Witte, Michael M.
Case, Michael G.
Yu, Peng
Henley, David B.
Hochstetler, Helen M.
D’Souza, Deborah N.
Trzepacz, Paula T.

April 2016

BackgroundClinical diagnosis of Alzheimer disease (AD) is challenging, with a 70.9%–87.3% sensitivit...

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Camus, Vincent
Payoux, Pierre
Barré, Louisa
Desgranges, Béatrice
Voisin, Thierry
Tauber, Clovis
La Joie, Renaud
Tafani, Mathieu
Hommet, Caroline
Chételat, Gaël
Mondon, Karl
de La Sayette, Vincent
Cottier, Jean-Philippe
Beaufils, Emilie
Ribeiro, Maria-Joao
Gissot, Valérie
Vierron, Emilie
Vercouillie, Johnny
Skovronsky, D.
Vellas, Bruno
Eustache, Francis
Guilloteau, Denis

April 2012

International audiencePURPOSE: Positron emission tomography (PET) imaging of brain amyloid load has ...

Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: The incremental diagnostic value of amyloid PET with [18F]-florbetapir (INDIA-FBP) study

Boccardi M.
Altomare D.
Ferrari C.
Festari C.
Guerra U. P.
Paghera B.
Pizzocaro C.
Lussignoli G.
Geroldi C.
Zanetti O.
Cotelli M. S.
Turla M.
Borroni B.
Rozzini L.
Mirabile D.
Defanti C.
Gennuso M.
Prelle A.
Gentile S.
Morandi A.
Vollaro S.
Volta G. D.
Bianchetti A.
Conti M. Z.
Cappuccio M.
Carbone P.
Bellandi D.
Abruzzi L.
Bettoni L.
Villani D.
Raimondi M. C.
Lanari A.
Ciccone A.
Facchi E.
Di Fazio I.
Rozzini R.
Boffelli S.
Manzoni L.
Salvi G. P.
Cavaliere S.
Belotti G.
Avanzi S.
Pasqualetti P.
Muscio C.
Padovani A.
Frisoni G. B.
Antelmi L.
Galluzzi S.
Pievani M.
Redolfi A.
Tarallo A.
Arora A.
Bertocchi M.
Chito E.
Moretti D. V.
Giubbini R.
Rodella C.
Camoni L.
Massetti V.
Andreoli M.
Bellelli G.
Fascendini S.
Mattioli F.
Turco R.
Vezzadini G.
Raimondi V.
Mondini S.
Zanacchi E. C.
Grigolo M.
Pezzini A.
Bilotti G.
Bigni B.
Zavarise P.
Ngonga G.
Anzola G. P.
Turrone R.
Guizzetti G.
Zanetti M.

January 2016

IMPORTANCE Cerebral amyloidosis is a key abnormality in Alzheimer disease (AD) and can be detected i...

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Camus, Vincent
Payoux, Pierre
Barré, Louisa
Desgranges, Béatrice
Voisin, Thierry
Tauber, Clovis
La Joie, Renaud
Tafani, Mathieu
Hommet, Caroline
Chételat, Gaël
Mondon, Karl
de La Sayette, Vincent
Cottier, Jean-Philippe
Beaufils, Emilie
Ribeiro, Maria-Joao
Gissot, Valérie
Vierron, Emilie
Vercouillie, Johnny
Skovronsky, D.
Vellas, Bruno
Eustache, Francis
Guilloteau, Denis

April 2012

International audiencePURPOSE: Positron emission tomography (PET) imaging of brain amyloid load has ...

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Camus, Vincent
Payoux, Pierre
Barré, Louisa
Desgranges, Béatrice
Voisin, Thierry
Tauber, Clovis
La Joie, Renaud
Tafani, Mathieu
Hommet, Caroline
Chételat, Gaël
Mondon, Karl
de La Sayette, Vincent
Cottier, Jean-Philippe
Beaufils, Emilie
Ribeiro, Maria-Joao
Gissot, Valérie
Vierron, Emilie
Vercouillie, Johnny
Skovronsky, D.
Vellas, Bruno
Eustache, Francis
Guilloteau, Denis

April 2012

International audiencePURPOSE: Positron emission tomography (PET) imaging of brain amyloid load has ...

18F-Florbetaben PET/CT to Assess Alzheimer's Disease: A new Analysis Method for Regional Amyloid Quantification

Alongi, Pierpaolo
Sardina, Davide Stefano
Coppola, Rosalia
Scalisi, Salvatore
Puglisi, Valentina
Arnone, Annachiara
Raimondo, Giorgio Di
Munerati, Elisabetta
Alaimo, Valerio
Midiri, Federico
Russo, Giorgio
Stefano, Alessandro
Giugno, Rosalba
Piccoli, Tommaso
Midiri, Massimo
Grimaldi, Luigi M E

January 2019

While AD can be definitively confirmed by postmortem histopathologic examination, in vivo imaging ma...

Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study

Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP)Working Group

January 2016

Cerebral amyloidosis is a key abnormality in Alzheimer disease (AD) and can be detected in vivo with...

The use of amyloid imaging in clinical praxis: a critical review

Nordberg, Agneta

February 2015

Recent development in molecular imaging enables measurement of fibrillar amyloid plaque in Alzheimer...

Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain

Richards, Danielle
Sabbagh, Marwan N.

December 2014

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting the elderly. Current ...

18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease

Filippi, Luca
Chiaravalloti, Agostino
Bagni, Oreste
Schillaci, Orazio

August 2018

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with tremendous impact...

18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease

Filippi, Luca
Chiaravalloti, Agostino
Bagni, Oreste
Schillaci, Orazio

August 2018

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with tremendous impact...

18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease

Filippi, Luca
Chiaravalloti, Agostino
Bagni, Oreste
Schillaci, Orazio

August 2018

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with tremendous impact...

18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease

Filippi, Luca
Chiaravalloti, Agostino
Bagni, Oreste
Schillaci, Orazio

August 2018

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with tremendous impact...

18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease

Filippi, L
Chiaravalloti, A
Bagni, O
Schillaci, O

August 2018

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with tremendous impact...

A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis

Perani Daniela
Schillaci Orazio
Padovani Alessandro
Nobili Flavio Mariano
Iaccarino Leonardo
Della Rosa Pasquale Anthony
Frisoni Giovanni
Caltagirone Carlo

January 2014

PET based tools can improve the early diagnosis of Alzheimer’s disease (AD) and differential diagnos...

Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia

Degenhardt, Elisabeth K.
Witte, Michael M.
Case, Michael G.
Yu, Peng
Henley, David B.
Hochstetler, Helen M.
D’Souza, Deborah N.
Trzepacz, Paula T.

April 2016

BackgroundClinical diagnosis of Alzheimer disease (AD) is challenging, with a 70.9%–87.3% sensitivit...

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Camus, Vincent
Payoux, Pierre
Barré, Louisa
Desgranges, Béatrice
Voisin, Thierry
Tauber, Clovis
La Joie, Renaud
Tafani, Mathieu
Hommet, Caroline
Chételat, Gaël
Mondon, Karl
de La Sayette, Vincent
Cottier, Jean-Philippe
Beaufils, Emilie
Ribeiro, Maria-Joao
Gissot, Valérie
Vierron, Emilie
Vercouillie, Johnny
Skovronsky, D.
Vellas, Bruno
Eustache, Francis
Guilloteau, Denis

April 2012

International audiencePURPOSE: Positron emission tomography (PET) imaging of brain amyloid load has ...

Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: The incremental diagnostic value of amyloid PET with [18F]-florbetapir (INDIA-FBP) study

Boccardi M.
Altomare D.
Ferrari C.
Festari C.
Guerra U. P.
Paghera B.
Pizzocaro C.
Lussignoli G.
Geroldi C.
Zanetti O.
Cotelli M. S.
Turla M.
Borroni B.
Rozzini L.
Mirabile D.
Defanti C.
Gennuso M.
Prelle A.
Gentile S.
Morandi A.
Vollaro S.
Volta G. D.
Bianchetti A.
Conti M. Z.
Cappuccio M.
Carbone P.
Bellandi D.
Abruzzi L.
Bettoni L.
Villani D.
Raimondi M. C.
Lanari A.
Ciccone A.
Facchi E.
Di Fazio I.
Rozzini R.
Boffelli S.
Manzoni L.
Salvi G. P.
Cavaliere S.
Belotti G.
Avanzi S.
Pasqualetti P.
Muscio C.
Padovani A.
Frisoni G. B.
Antelmi L.
Galluzzi S.
Pievani M.
Redolfi A.
Tarallo A.
Arora A.
Bertocchi M.
Chito E.
Moretti D. V.
Giubbini R.
Rodella C.
Camoni L.
Massetti V.
Andreoli M.
Bellelli G.
Fascendini S.
Mattioli F.
Turco R.
Vezzadini G.
Raimondi V.
Mondini S.
Zanacchi E. C.
Grigolo M.
Pezzini A.
Bilotti G.
Bigni B.
Zavarise P.
Ngonga G.
Anzola G. P.
Turrone R.
Guizzetti G.
Zanetti M.

January 2016

IMPORTANCE Cerebral amyloidosis is a key abnormality in Alzheimer disease (AD) and can be detected i...

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Camus, Vincent
Payoux, Pierre
Barré, Louisa
Desgranges, Béatrice
Voisin, Thierry
Tauber, Clovis
La Joie, Renaud
Tafani, Mathieu
Hommet, Caroline
Chételat, Gaël
Mondon, Karl
de La Sayette, Vincent
Cottier, Jean-Philippe
Beaufils, Emilie
Ribeiro, Maria-Joao
Gissot, Valérie
Vierron, Emilie
Vercouillie, Johnny
Skovronsky, D.
Vellas, Bruno
Eustache, Francis
Guilloteau, Denis

April 2012

International audiencePURPOSE: Positron emission tomography (PET) imaging of brain amyloid load has ...

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Camus, Vincent
Payoux, Pierre
Barré, Louisa
Desgranges, Béatrice
Voisin, Thierry
Tauber, Clovis
La Joie, Renaud
Tafani, Mathieu
Hommet, Caroline
Chételat, Gaël
Mondon, Karl
de La Sayette, Vincent
Cottier, Jean-Philippe
Beaufils, Emilie
Ribeiro, Maria-Joao
Gissot, Valérie
Vierron, Emilie
Vercouillie, Johnny
Skovronsky, D.
Vellas, Bruno
Eustache, Francis
Guilloteau, Denis

April 2012

International audiencePURPOSE: Positron emission tomography (PET) imaging of brain amyloid load has ...

18F-Florbetapir and 18F-FDG PET studies in the diagnostic evaluation of Alzheimer's disease

Abstract

Extracted data

18F-Florbetapir and 18F-FDG PET studies in the diagnostic evaluation of Alzheimer's disease

Abstract

Extracted data

Related items

Related items